Search

Displaying results 1981 - 1990 of 2158 in total
  1. Drug

    Rivanicline

    go.drugbank.com/drugs/DB05855
    Experimental

    Rivanicline (TC-2403, RJR-2403, (E)-metanicotine) is a partial agonist at neuronal nicotinic acetylcholine receptors, binding primarily to the α4β2 subtype.

    Synonyms: (E)-metanicotine, (3E)-N-methyl-4-(pyridin-3-yl)but-3-en-1-amine
  2. Drug

    Obeticholic acid

    go.drugbank.com/drugs/DB05990
    ApprovedInvestigational

    [A192786] Obeticholic acid is a farnesoid-X receptor (FXR) agonist used to treat this condition, possibly allowing for increased survival.

    Categories: Farnesoid X Receptor Agonist, Farnesoid X Receptor Agonists
  3. Drug

    Glembatumumab vedotin

    go.drugbank.com/drugs/DB05996
    Investigational

    A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.

  4. Drug

    Endostatin

    go.drugbank.com/drugs/DB06423
    Investigational

  5. Drug

    VIR201

    go.drugbank.com/drugs/DB05110
    Experimental

    is an experimental therapeutic vaccine currently in clinical trial. The aim of therapeutic vaccines is to augment the body's immune response to HIV and to delay or prevent progression to AIDS.

  6. Drug

    Thymectacin

    go.drugbank.com/drugs/DB05116
    Investigational

    Thymectacin, a phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine, is a novel small molecule anticancer agent.

  7. Drug

    Acimtamig

    go.drugbank.com/drugs/DB18674
    Investigational

    Acimtamig is a tetravalent bispecific chimeric anti-human CD30 x anti-human CD16A recombinant antibody construct.

    Synonyms: AFM13 (ANTI CD30 X ANTI CD16), tetravalent bispecific chimeric anti-human CD30 x anti-human CD16A recombinant antibody construct
  8. Drug

    RC88

    go.drugbank.com/drugs/DB18697
    Experimental

    RC88 is an antibody-drug conjugate comprising a humanized anti-mesothelin monoclonal antibody conjugated to monomethyl auristatin E (MMAE).

  9. Drug

    Tisotumab vedotin

    go.drugbank.com/drugs/DB16732
    ApprovedInvestigational

    Tisotumab vedotin is a tissue factor-directed antibody-drug conjugate (ADC) comprised of an anti-tissue factor (TF) human IgG1-kappa antibody conjugated to monomethyl auristatin E (MMAE), a microtubule-disrupting

  10. Drug

    Resamirigene bilparvovec

    go.drugbank.com/drugs/DB16779
    Investigational

    AT132 is under investigation in clinical trial NCT03199469 (Gene Transfer Clinical Study in X-linked Myotubular Myopathy).